Get the Stockscreener App
66.57
0.14%
0.09
Pre-market:
67.56
0.99
+1.49%
Arcellx Inc stock is traded at $66.57, with a volume of 684.47K.
It is up +0.14% in the last 24 hours and down -11.87% over the past month.
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
See More
Previous Close:
$66.48
Open:
$67.07
24h Volume:
684.47K
Relative Volume:
1.13
Market Cap:
$3.60B
Revenue:
$155.82M
Net Income/Loss:
$-40.42M
P/E Ratio:
-93.76
EPS:
-0.71
Net Cash Flow:
$3.58M
1W Performance:
+2.97%
1M Performance:
-11.87%
6M Performance:
+6.41%
1Y Performance:
+20.45%
1-Day Range:
$65.75
$67.80
1-Week Range:
$63.62
$68.24
52-Week Range:
$47.88
$107.37
Arcellx Inc Stock (ACLX) Company Profile
Name
Arcellx Inc
Sector
Industry
Phone
240-327-0603
Address
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
66.57 | 3.60B | 155.82M | -40.42M | 3.58M | -0.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Sep-03-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Mar-07-24 | Initiated | Morgan Stanley | Overweight |
| Jan-04-24 | Reiterated | Needham | Buy |
| Dec-19-23 | Initiated | Scotiabank | Sector Outperform |
| Oct-30-23 | Initiated | TD Cowen | Outperform |
| Oct-17-23 | Initiated | UBS | Buy |
| May-18-23 | Initiated | Truist | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
| Mar-14-23 | Initiated | Stifel | Buy |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-13-22 | Resumed | BofA Securities | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-27-22 | Initiated | Needham | Buy |
| Jul-20-22 | Initiated | Canaccord Genuity | Buy |
| Mar-01-22 | Initiated | BofA Securities | Buy |
| Mar-01-22 | Initiated | SVB Leerink | Outperform |
View All
Arcellx Inc Stock (ACLX) Latest News
Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Expands By 6.6% - MarketBeat
Arcellx, Inc.: Trying To Build A Better Myeloma Cell Therapy - Seeking Alpha
Arcellx director Kavita Patel sells $98,801 in stock By Investing.com - Investing.com Australia
Arcellx, Inc. (NASDAQ:ACLX) Director Kavita Patel Sells 1,500 Shares - MarketBeat
Arcellx director Kavita Patel sells $98,801 in stock - Investing.com India
(ACLX)Analyzing Arcellx's Short Interest - Benzinga
Oversold Conditions For Arcellx (ACLX) - Nasdaq
Arcellx, Inc. (NASDAQ:ACLX) Insider Sells $261,820.57 in Stock - MarketBeat
Arcellx's chief medical officer sells shares worth $581,315 By Investing.com - Investing.com Australia
arcellx CEO Elghandour sells stock worth $2.26 million By Investing.com - Investing.com Nigeria
Arcellx CFO Michelle Gilson sells shares worth $700,959 By Investing.com - Investing.com Australia
arcellx CEO Elghandour sells stock worth $2.26 million - Investing.com
Arcellx CFO Michelle Gilson sells shares worth $700,959 - Investing.com India
Arcellx Breaks Below 200-Day Moving AverageNotable for ACLX - Nasdaq
Arcellx, Inc. (NASDAQ:ACLX) Shares Sold by JPMorgan Chase & Co. - MarketBeat
Arcellx's chief medical officer sells shares worth $498,795 By Investing.com - Investing.com Australia
Arcellx CFO Michelle Gilson sells $831,378 in stock By Investing.com - Investing.com Nigeria
Principal Financial Group Inc. Has $336,000 Stock Position in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Arcellx CEO Rami Elghandour sells shares worth $2.24 million By Investing.com - Investing.com Australia
Arcellx chief medical officer sells shares worth $498,795 By Investing.com - Investing.com Canada
Arcellx chief medical officer sells shares worth $498,795 - Investing.com
Christopher Heery Sells 3,061 Shares of Arcellx, Inc. (NASDAQ:ACLX) Stock - MarketBeat
Christopher Heery Sells 3,301 Shares of Arcellx, Inc. (NASDAQ:ACLX) Stock - MarketBeat
Arcellx CEO Rami Elghandour sells shares worth $2.24 million - Investing.com
Arcellx CFO Michelle Gilson sells $831,378 in stock - Investing.com India
Arcellx (NASDAQ:ACLX) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Receives $105.93 Consensus Price Target from Analysts - MarketBeat
Viking stock among buyout targets: Oppenheimer (VKTX:NASDAQ) - Seeking Alpha
(ACLX) On The My Stocks Page - Stock Traders Daily
Arcellx Stock Earns 82 Relative Strength Rating - Yahoo! Voices
arcellx director Kavita Patel sells shares worth $115,450 - Investing.com India
arcellx director Kavita Patel sells shares worth $115,450 By Investing.com - Investing.com Nigeria
5 Biotech Breakthrough Stocks to Watch in 2025 - Yahoo Finance
Arcellx Inc Stock (ACLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):